Concord Biotech Limited (BOM:543960)

India flag India · Delayed Price · Currency is INR
1,681.30
-4.65 (-0.28%)
At close: Aug 29, 2025
-0.28%
Market Cap175.93B
Revenue (ttm)11.88B
Net Income (ttm)3.56B
Shares Outn/a
EPS (ttm)34.03
PE Ratio49.40
Forward PE39.69
Dividend10.70 (0.66%)
Ex-Dividend DateSep 3, 2025
Volume1,257
Average Volume4,447
Open1,691.85
Previous Close1,685.95
Day's Range1,676.60 - 1,717.25
52-Week Range1,370.05 - 2,658.00
Betan/a
RSI44.39
Earnings DateAug 13, 2025

About Concord Biotech

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin,... [Read more]

Industry Pharmaceutical Preparations
Founded 1984
Employees 1,571
Stock Exchange Bombay Stock Exchange
Ticker Symbol 543960
Full Company Profile

Financial Performance

In 2024, Concord Biotech's revenue was 12.00 billion, an increase of 18.01% compared to the previous year's 10.17 billion. Earnings were 3.72 billion, an increase of 20.62%.

Financial Statements

News

There is no news available yet.